Moderna to Present at Upcoming Conferences in March 2026
Rhea-AI Summary
Moderna (Nasdaq:MRNA) will present at two investor conferences in March 2026. Presentations are scheduled for TD Cowen 46th Annual Healthcare Conference on March 3, 2026 at 1:50 PM ET and Barclays 28th Annual Global Healthcare Conference on March 10, 2026 at 9:30 AM ET.
A live webcast will be available under Events and Presentations in the Investors section at investors.modernatx.com, with replays archived for at least 30 days after each presentation.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MRNA
On the day this news was published, MRNA gained 6.65%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 60 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $1.23B to the company's valuation, bringing the market cap to $19.71B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MRNA gained 6.08% while only one scanned peer (ABVX) was up 3.31% and broader biotech peers showed mixed moves, pointing to a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Regulatory update | Positive | +6.1% | FDA accepted BLA for mRNA-1010 with PDUFA goal date set. |
| Feb 17 | Regulatory approval | Positive | +4.0% | EU marketing authorization for COVID-19 vaccine mNEXSPIKE. |
| Feb 13 | Earnings and guidance | Mixed | +5.3% | Q4/FY 2025 results with losses but cost cuts and 2026 growth plan. |
| Feb 10 | Regulatory setback | Negative | +0.1% | FDA Refusal-to-File for mRNA-1010 BLA due to comparator choice. |
| Feb 10 | Partnership deal | Positive | +0.1% | Five-year strategic agreement with Mexico for vaccines and tech transfer. |
Recent news, including regulatory updates and earnings, has generally been followed by positive price moves, with even negative regulatory items seeing mildly positive reactions.
Over recent weeks, Moderna reported multiple major updates, including an FDA Refusal-to-File for its flu vaccine on Feb 10, a strategic Mexico agreement, Q4 and FY 2025 results, and later an FDA decision to initiate review of its flu vaccine with a Aug 5, 2026 PDUFA goal date. These events tended to coincide with positive price reactions, suggesting investors focused on long-term pipeline and financial trajectory rather than single setbacks. Today’s conference participation notice fits into this ongoing investor communication cadence.
Market Pulse Summary
The stock moved +6.7% in the session following this news. A strong positive reaction aligns with a stretch of supportive news, including recent regulatory progress and earnings updates, where prior items saw gains of up to 6.08%. The current announcement mainly highlights upcoming investor conferences and webcasts, suggesting the move has more to do with earlier catalysts than this routine disclosure. Investors may weigh how sustained optimism balances against insider net selling over the last 90 days and broader biotech volatility.
AI-generated analysis. Not financial advice.
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
TD Cowen 46th Annual Healthcare Conference, on Tuesday, March 3rd at 1:50pm ET
Barclays 28th Annual Global Healthcare Conference, on Tuesday, March 10th at 9:30am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire